This list contains references from the content that can be linked to their source. For a full set of references and notes please see the PDF or HTML where available.
1R Sing , A Barden , T Mori , (2001) Advanced glycation end products: a review. Diabetologia 44, 129–146.
4 H Vlassara (1996) Advanced glycation end products and atherosclerosis. Ann Med 28, 419–426.
5TJ Lyons , G Silvestri , JA Dunn , (1991) Role of glycation in modification of lens crystallins in diabetic and nondiabetic senile cataracts. Diabetes 40, 1010–1015.
6M Brownlee (1995) Advanced protein glycosylation in diabetes and aging. Annu Rev Med 46, 223–234.
7 VV Shuvaev , I Laffont , JM Serot , (2001) Increased protein glycation in cerebrospinal fluid of Alzheimer's disease. Neurobiol Aging 22, 397–402.
9 MS Kumar , PY Reddy , PA Kumar , (2004) Effect of dicarbonyl-induced browning on α-crystallin chaperone-like activity: physiological significance and caveats of in vitro aggregation assays. Biochem J 379, 273–282.
10HT Beswick & JJ Harding (1987) Conformational changes induced in lens α- and γ-crystallins by modification with glucose 6-phosphate. Implications for cataract. Biochem J 246, 761–769.
11A Stitt , TA Gardiner , NL Alderson , (2002) The AGE inhibitor pyridoxamine inhibits development of retinopathy in experimental diabetes. Diabetes 51, 2826–2832.
12R Wada , Y Nishizawa , N Yagihashi , (2001) Effects of OPB-9195, anti-glycation agent, on experimental diabetic neuropathy. Eur J Clin Invest 31, 513–520.
13S Vasan , X Zhang , X Zhang , (1996) An agent cleaving glucose-derived protein crosslinks in vitro and in vivo. Nature 382, 275–278.
14D Edelstein & M Brownlee (1992) Mechanistic studies of advanced glycosylation end product inhibition by aminoguanidine. Diabetes 41, 26–29.
15BI Freedman , JP Wuerth , K Cartwright , (1999) Design and baseline characteristics for the aminoguanidine Clinical Trial in Overt Type 2 Diabetic Nephropathy (ACTION II). Control Clin Trials 20, 493–510.
16T Taguchi , M Sugiura , Y Hamada , (1998) In vivo formation of a Schiff base of aminoguanidine with pyridoxal phosphate. Biochem Pharmacol 55, 1667–1671.
18JK Grover , S Yadav & V Vats (2002) Medicinal plants of India with antidiabetic potentials. J Ethnopharmacol 81, 81–100.
20T Mrudula , P Suryanarayana , PN Srinivas , (2007) Effect of curcumin on hyperglycemia-induced vascular endothelial growth factor expression in streptozotocin-induced diabetic rat retina. Biochem Biophys Res Commun 361, 528–532.
21PA Kumar , PY Reddy , PN Srinivas , (2009) Delay of diabetic cataract in rats by the antiglycating potential of cumin through modulation of α-crystallin chaperone activity. J Nutr Biochem 20, 553–562.
23W Kusirisin , S Srichairatanakool , P Lerttrakarnnon , (2009) Antioxidative activity, polyphenolic content and anti-glycation effect of some Thai medicinal plants traditionally used in diabetic patients. Med Chem 5, 139–147.
24T Nakagawa , T Yokozawa , K Terasawa , (2002) Protective activity of green tea against free radical- and glucose-mediated protein damage. J Agric Food Chem 50, 2418–2422.
25T Nagasawa , N Tabata , Y Ito , (2003) Dietary G rutin suppresses glycation in tissue proteins of streptozotocin induced diabetic rats. Mol Cell Biochem 252, 141–147.
26S Pashikanti , DR de Alba , GA Boissonneault , (2010) Rutin metabolites: novel inhibitors of nonoxidative advanced glycation end products. Free Radic Biol Med 48, 656–663.
27PA Kumar , MS Kumar , GB Reddy , (2007) Effect of glycation on alpha-crystallin structure and chaperone-like function. Biochem J 408, 251–258.
28K Uchida , M Kanematsu , K Sakai , (1998) Protein-bound acrolein: potential markers for oxidative stress. Proc Natl Acad Sci U S A 95, 4882–4887.
29 DL Price , PM Rhett , SR Thorpe , (2001) Chelating activity of advanced glycation end-product inhibitors. J Biol Chem 276, 48967–48972.
30JE Brown , H Khodr , RC Hider , (1998) Structural dependence of flavonoid interactions with Cu2+ ions: implications for their antioxidant properties. Biochem J 330, 1173–1178.
32P Suryanarayana , M Saraswat , T Mrudula , (2005) Curcumin and turmeric delay streptozotocin-induced diabetic cataract in rats. Invest Ophthalmol Vis Sci 46, 2092–2099.
34K Ikeda , T Higashi , H Sano , (1996) ɛ-(Carboxymethyl) lysine protein adduct is a major immunological epitope in proteins modified with advanced glycation end products of the Maillard reaction. Biochemistry 35, 8075–8083.
35RH Nagaraj , IN Shipanova & FM Faust (1996) Protein cross-linking by the Maillard reaction. Isolation, characterization, and in vivo detection of a lysine–lysine cross-link derived from methylglyoxal. J Biol Chem 271, 19338–19345.
36MU Ahmed , E Brinkmann-Frye , TP Degenhardt , (1997) N-epsilon-(carboxyethyl)lysine, a product of the chemical modification of proteins by methylglyoxal, increases with age in human lens proteins. Biochem J 324, 565–570.
39GB Sajithlal , P Chithra & G Chandrakasan (1998) The role of metal-catalyzed oxidation in the formation of advanced glycation end products: an in vitro study on collagen. Free Radic Biol Med 25, 265–269.
41S Wild , G Roglic , A Green , (2004) Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27, 1047–1053.
42T Nagasawa , N Tabata , Y Ito , (2003) Inhibition of glycation reaction in tissue protein incubations by water soluble rutin derivative. Mol Cell Biochem 249, 3–10.
43D Cervantes-Laurean , DD Schramm , EL Jacobson , (2006) Inhibition of advanced glycation end product formation on collagen by rutin and its metabolites. J Nutr Biochem 17, 531–540.
44LA Griffiths & A Barrow (1972) Metabolism of flavonoid compounds in germ-free rats. Biochem J 130, 1161–1162.
45H Matsuda , T Wang , H Managi , (2003) Structural requirements of flavonoids for inhibition of protein glycation and radical scavenging activities. Bioorg Med Chem 11, 5317–5323.